Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Trevi Therapeutics on September 29. The company’s shares closed yesterday at $9.56.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Khurshid covers the Healthcare sector, focusing on stocks such as aTyr Pharma, Rhythm Pharmaceuticals, and ANI Pharmaceuticals. According to TipRanks, Khurshid has an average return of 30.4% and a 58.04% success rate on recommended stocks.
Currently, the analyst consensus on Trevi Therapeutics is a Strong Buy with an average price target of $21.13, implying a 121.03% upside from current levels. In a report released on September 19, JonesTrading also reiterated a Buy rating on the stock with a $25.00 price target.
TRVI market cap is currently $1.14B and has a P/E ratio of -22.72.
Read More on TRVI:
Disclaimer & DisclosureReport an Issue
- Trevi Therapeutics: Buy Rating Affirmed Amid Promising Haduvio Trial Data and Strategic Market Expansion
- CoreWeave upgraded, Instacart downgraded: Wall Street’s top analyst calls
- Trevi Therapeutics initiated with an Overweight at Morgan Stanley
- Trevi Therapeutics CFO Resignation Announced
- Trevi Therapeutics: Optimism Amid Earnings Call Insights
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
